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ABSTRACT:  
Kruppel-like factor 3 (KLF3) is a transcriptional regulator that we have shown to be involved in the 
regulation of adipogenesis in vitro. Here, we report that KLF3-null mice are lean and protected 
from diet-induced obesity and glucose intolerance. On a chow diet, plasma levels of leptin are 
decreased, and adiponectin is increased. Despite significant reductions in body weight and 
adiposity, wild-type and knockout animals show equivalent energy intake, expenditure, and 
excretion. To investigate the molecular events underlying these observations, we used microarray 
analysis to compare gene expression in [Klf3.sup.+/+] and [Klf3.sup.-/-] tissues. We found that 
mRNA expression of Fam132a, which encodes a newly identified insulin-sensitizing adipokine, 
adipolin, is significantly upregulated in the absence of KLF3. We confirmed that KLF3 binds the 
Fam132a promoter in vitro and in vivo and that this leads to repression of promoter activity. 
Further, plasma adipolin levels were significantly increased in [Klf3.sup.-/-] mice compared with 
wild-type littermates. Boosting levels of adipolin via targeting of KLF3 offers a novel potential 
therapeutic strategy for the treatment of insulin resistance. 
 
 
The mechanisms linking obesity and the development of insulin resistance are not well 
understood despite intensive research (1,2). An improved understanding of the molecular control 
of metabolism, and how nutrition and environmental factors can influence gene expression to 
modulate metabolic pathways, is critical for the development of successful therapeutics to treat 
metabolic disorders, such as type 2 diabetes. Numerous transcriptional regulators have been 
implicated in physiological responses to metabolic stimuli, and the pathways and downstream 
effectors involved in these processes are now beginning to be elucidated. One family of regulators 
that play diverse roles in metabolism is the Kruppel-like factor (KLF) family of transcription factors 
(3-5). 
 KLFs are a family of evolutionarily conserved, zinc-finger transcription factors, which 
recognize and bind to GC-rich sequences and CACCC boxes in the promoters and enhancers of 
their target genes (3). With the exception of KLF1, family members are widely expressed and 
have diverse biological roles (6,7). Several KLFs have been implicated in adipogenesis; KLF4, 
KLF5, KLF6, KLF9, and KLF15 (8-12) all positively regulate, while KLF2, KLF3, and KLF7 (13-15) 
inhibit adipogenesis. KLFs also regulate other aspects of metabolism. KLF15 has been shown to 
induce Glut4 expression in 3T3-L1 cells (16), and [Klf15.sup.-/-] mice demonstrate abnormal 
gluconeogenesis, leading to severe hypoglycemia after fasting (17). KLF11 can bind and regulate 
expression of the insulin promoter in pancreatic [beta]-cells, and a number of KLF11 single 
nucleotide polymorphisms show significant association with susceptibility to type 2 diabetes (18). 
A Japanese study linked a KLF7 variant to type 2 diabetes risk (19), while a different 
polymorphism has been shown to protect against obesity in a Danish population (20). Single 
nucleotide polymorphisms in the maternally imprinted KLF14 gene locus have been shown to 
affect expression of numerous adipocyte genes and are also associated with a number of 
metabolic disorders, including type 2 diabetes and elevated HDL cholesterol (21). Collectively, 
numerous studies place KLFs as important regulators of metabolism. 
 We have been studying the role of KLF3/BKLF as a regulator of adipocyte biology (22). 
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We have previously reported that [Klf3.sup.-/-] mice are lean, partly due to reduced adipose tissue 
mass and adipocyte size (14). As adipose is a focal point for a number of mechanisms linking 
obesity and insulin resistance, including altered adipocyte secretory profile, we set out to consider 
the role of KLF3 on whole-body metabolism and insulin action. We used a microarray-based 
approach to compare tissues and cells derived from [Klf3.sup.-/-] mice and wild-type littermates 
and identified Fam132a as a highly upregulated KLF3 target gene in a number of tissues. Very 
recently, two independent laboratories identified FAM132A, also known as C1QDC2 (C1q 
domain-containing protein 2), CTRP12 (C1q/ tumor necrosis factor-related protein 12) and 
adipolin (adipose-derived insulin-sensitizing factor), as a new factor positively influencing glucose 
homeostasis (23,24). 
 In this study, we verified a direct in vivo interaction between KLF3 and the Fam132a 
promoter by chromatin immunoprecipitation (CHIP) studies and show systemic upregulation of 
Fam132a mRNA expression and plasma adipolin levels in mice that lack KLF3. We have also 
further characterized the metabolic phenotype of [Klf3.sup.-/-] mice on chow and high-fat diets to 
understand the role of KLF3 in the regulation of body weight, composition, and energy 
metabolism. Importantly, we show that KLF3-null mice are protected from diet-induced obesity 
and have improved insulin resistance. These data suggest a molecular mechanism whereby KLF3 
may orchestrate effects on metabolism via regulation of factors such as the insulin-sensitizing 
hormone adipolin and imply that the improved metabolic profile in the absence of KLF3 may 
result, at least in part, from a significant elevation in Fam132a transcription and circulating 
adipolin levels. 
 
RESEARCH DESIGN AND METHODS 
 
Approval for the use of animals was from the University of Sydney Animal Care and Ethics 
Committee (protocol: L02/7-2009/3/5054). [Klf3.sup.-/-] mice on an FVB/ NJ background were 
generated as previously described (14). Mice were weaned at 3 weeks and fed standard chow 
(6% kcal from fat, 14.3 MJ/kg; Specialty Feeds, Glen Forest, Western Australia, Australia) or high-
fat diet (45% kcal from fat [mainly lard], 21.8 MJ/kg; made in house) until age 12 weeks. 
 
Adipocyte histology. Epididymal adipose tissue (n = 34 per group) was fixed in 4% 
paraformaldehyde in PBS for 48 h at 4[degrees]C. Samples were washed in PBS, dehydrated 
through graded ethanol solutions, and paraffin embedded. Sections (5 [micro]m) were stained 
with hematoxylin-eosin (Sigma-Aldrich). The size of 200-300 adipocytes was measured per 
mouse at x20 magnification (AnalySIS FIVE; Olympus). 
 
Glucose and insulin tolerance tests. Glucose tolerance tests were performed on overnight-
fasted mice. After determination of fasting blood glucose, mice were given an intraperitoneal 
injection of 50% glucose solution (2 g/kg). For insulin tolerance tests, mice were fasted 4 h and 
given an intraperitoneal injection of 1 unit/kg insulin (Actrapid; Novo Nordisk). For both tests, taft 
blood glucose was measured using an Accu-chek Performa glucometer (Roche). 
 
Energy metabolism. Food intake was measured for mice housed individually with a custom-
made cage insert (City West Plastics, Rydalmere, Australia) designed to catch spilled food. Mice 
were given 24 h to acclimatize, after which food was weighed dally for 3 days. 
 For calculation of total energy expenditure, whole-body lean and fat mass was determined 
by dual-energy X-ray absurptiometry (Lunar PIXImus2 mouse densitometer; GE Healthcare). 
[Vo.sub.2] was measured at 22[degrees]C using an indirect calorimetry system (Oxymax series; 
Columbus Instruments, Columbus, OH). Studies commenced after 2 h of acclimation to the 
metabolic chamber. [Vo.sub.2] was measured in individual mice at 20- to 30-min intervals over a 
48-h period. Energy excreted in feces was measured using a bomb calorimeter (model 1356; 
PARR Instrument Company). Feces was compacted and dried in a freeze dryer overnight before 
combustion. 
 
Plasma biochemistry. Plasma leptin, insulin, and adiponectin were measured by ELISA 
according to the manufacturer's guidelines (Quantikine Mouse Leptin and Adiponectin, R&D 
Systems, Minneapolis, MN; Ultrasentivite Mouse Insulin ELISA, Mercodia, Uppsala, Sweden). 
Plasma nonesterilied fatty acid (NEFA), glycerol, and triglyceride were determined by colorimetric 
assay per the manufacturer's instructions (NEFA-C assay kit; Wako Chemicals, Osaka, Japan; 
serum triglyceride (and glycerol) determination kit; Sigma-Aldrich, Sydney, NSW, Australia). 
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Electrophoretic mobility shift assays. Electrophoretic mobility shift assays (EMSAs) were 
carried out as previously described (25). Oligonucleotides used in the synthesis of radiolabeled 
probes were as follows: mouse Fam132a promoter probe A, 5-
TGCTCCGCCCCGCCCCGCCCCGCCCTGCTCC-3 and 5-GGAGCAGGG 
CGGGGGGGCGGGGCGGAGCA-3; Fam132a probe B, 5-GGTCCCGCCCCG 
CCCTGCCCCGCCCCGCCCTGCTCC-3 and 5-GGAGCAGGGCGGCGGGGCAG 
GGCGGGGCGGGACC-3; Fam132a probe C, 5-TGCCCCGCCCCGCCCTGCTCCG 
CCCCGCCCCGCCCC-3 and 5- GGGGCGGGGCGGGGCGGAGCAGGGCGGGGCG GGGCA-3; 
and Klf8 promoter, 5- GGGCCCGCCCCACCCCCTCCT-3 and 5-AGGA 
GGGGGTGGGGCGGGCCC-3. 
 
Cloning of the Fam132a promoter for transactivation assays. Plasmid pGL4.10[luc2]-
Fam132a promoter contained the sequence from -150 to + 100 of the Fam132a promoter; for 
pGL4.10[luc2]-Fam132a-[DELTA]CACCC, the sequence from -101 to -29 was deleted. 
 
Transactivation assays. SL-2 cells were transfected in sixwell plates using the calcium 
phosphate method (26), and 3T3-L1 cells were transfected using Fugene 6 (Promega). For SL2 
cells, 250 ng pPac-KLF1 and 0, 25, 50, and 250 ng pPac-KLP3 were transfected along with 1 
[micro]g pGL4.10[luz2], pGL4.10[luc2]-Fam132a pro-rooter, or pGL4.10[luc2]-Fam132a-
[DELTA]CACCC. For 3T3-L1 cells, 0, 50, 250, and 500 ng pCDNA3-KLF3 was transfected along 
with 1 [micro]g pGL4.10[luc2], pGL4.10[luc2]-Fam132a promoter, or pGL4.10[luc2]-Fam132a-
[DELTA]CACCC. For all transfections, 0.1 [micro]g pGL4.74[hRluc/TK] was included as a 
transfection control. Forty-eight hours posttransfection, the cells were lysed and assayed for 
luciferase activity by using a dual luciferase reporter assay system (Promega). In all cases, 
reporter activity was normalized with respect to Renilla luciferase levels. 
 
Western blotting. Diluted plasma (5 [micro]L; 1:20 in PBS), equivalent to 0.25 [micro]L total 
plasma, was subjected to SDS-PAGE. Proteins were transferred to polyvinylidene fluoride 
membranes and incubated with primary antibody (anti-Fam132a, Santa Cruz sc-241304) followed 
by horseradish peroxidase--corljugated anti-goat IgG secondary. Signals were visualized using 
Immobilon Western Chemiluminescent horseradish peroxidase substrate (Millipore). Membranes 
were exposed to film and scanned on a densitometer and band densities quantitated with IPLab 
software (IPLab Gel H; Signal Analytics). 
 
ChIP assay. ChIP assays were preformed as previously described (27), using a Biorupter for 
chromatin sonication (Diagenode, Liege, Belgium). Chromatin was immunoprecipitated from 
murine erythroleukemia cells after induction of erythroid differentiation in 1.8% DMSO (28), using 
either the Pierce anti-KLF3 antibody (PA5-18030) or rabbit polyclonal anti-KLF3 serum (29). Real-
time PCR primers were as follows: Fam132a promoter, 5-GATTCGCTTCCCTGG AGGTGTGG-3 
and 5-GCCCAGTCTCTGGTCTCCTCTCT-3; C/ebp[alpha] promoter, 5-
AGGAGAAGGCGGGCTCTAAG-3 and 5-ATCGAAGGCGCCAGTAGGA-3; C/ebp[alpha] negative 
control (5 kb upstream of C/ebp[alpha] exon 1), 5-CCCAGGCAGA ACAAAACATAGG-3 and 5-
GGGCAGGCCATTGTITTGTA-3; Klf8 promoter la, 5-CCAGCTCGTGCACACTGAA-3 and 5-
GAAGCCTTAACATCAGGAGTGGAA-3; Klf8 negative control 1 (4.5 kb upstream of Klf8 exon la), 
5-GGTTTCTGAG ACCTAACACTTCACACT-3 and 5-CCATTTAGTCATCCAGCGAACAA-3; and 
Klf8 negative control 2 (33 kb downstream of Klf8 exon 1a), 5-AACCTG GGTGCCTCCTTGTA-3 
and 5-TCATGCCTTTGACTTTAGTGCTTT-3; 
 
Determination of mRNA expression. RNA extraction, cDNA synthesis, and quantification were 
performed as previously described (28,30). Oligonucleotides were as follows: ribosomal 18S: 5-
GACGGACCAGAGCGAAAGC-3 and 5-AACTCCGACTTTCGTTCTTGATT-3, and Fam132a, 5-
GATTCACAGCCCC AGTCTCT-3 and 5-ACAGATGAGAACACGGACCA-3 or 5-
GGTCTTCACAGT GCAGGTTCAG-3 and 5-GACTGCCCCAGAACTGTTGTC-3. 
 
Statistical analysis. Data are presented as means [+ or -] SEM. One-way ANOVA was used to 
compare data from different genotypes and diet groups followed by pairwise comparisons using t 
tests with a Bonferroni correction to identify differences between groups. For energy expenditure 
data, ANCOVA analysis was performed using lean body mass as a covariate. All statistical 
analyses were completed using R (version 2.13.1; R Foundation for Statistical Computing, 
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Vienna, Austria), and P < 0.05 was considered statistically significant. 
 
RESULTS 
 
[Klf3.sup.-/-] mice are resistant to diet-induced obesity. In agreement with our previous 
observations (14), male [Klf3.sup.-/-] mice are shorter in length than their wild-type littermates and 
maintained a lower body weight and white adipose tissue (WAT) mass when fed a chow diet (Fig. 
1A, B, and D). On a high-fat diet, [Klf3.sup.-/-] mice were significantly and consistently lighter than 
either [Klf3.sup.+/+] or [Klf3.sup.+/-] littermates (Fig. 1C). Both subcutaneous (inguinal) and 
visceral (epididymal and retroperitoneal) WAT mass increased in mice in response to the high-fat 
diet, but [Klf3.sup.-/-] mice maintained less adiposity than [Klf3.sup.+/+] mice (Fig. 1E). The 
reduction in adiposity in [Klf3.sup.-/-] mice was selective for WAT. Subscapular brown adipose 
tissue depots from [Klf3.sup.-/-] mice weighed the same as brown adipose tissue from wild-type or 
heterozygote littermates despite their lower body weight (Fig. 1D and E). Liver weight was 
significantly lower in [Klf3.sup.-/-] mice on both the chow and high-fat diet (Fig. 1F and G). White 
adipocytes of [Klf3.sup.-/-] male mice were visibly smaller than those of [Klf3.sup.+/+] mice on 
both chow and high-fat diets (Fig. 1H). We also compared the size distribution of fat cells in 
[Klf3.sup.+/+] and [Klf3.sup.-/-] male mice by measuring the diameter of epididymal adipocytes 
(Fig. 1I). We found that high-fat feeding noticeably increased the maximum and average 
adipocyte size in [Klf3.sup.+/+] mice but had little effect in [Klf3.sup.-/-] animals (Fig. 1I). 
 Loss of KLF3 does not alter energy intake or expenditure. To investigate the lean 
phenotype of [Klf3.sup.-/-] mice, we compared energy intake and expenditure between wild-type 
mice and knockout littermates. [Klf3.sup.-/-] mice consumed the same amount of food as wild-type 
littermates on both chow and high-fat diets when expressed as kJ/day (Fig. 2A) or when corrected 
for body weight (data not shown). Similarly, loss of KLF3 did not appear to alter fecal weight or 
energy content on either diet (Fig. 2B). Furthermore, total energy expenditure was not affected by 
Klf3 deficiency when expressed per mouse or per gram of lean body mass, as determined by 
dual-energy X-ray absorptiometry (Fig. 2C-E). High-fat feeding significantly increased energy 
expenditure in wild-type and [Klf3.sup.-/-] mice (Fig. 2F). 
 [Klf3.sup.-/-] mice are protected from diet-induced glucose intolerance. For assessment of 
the effect of KLF3 deficiency on systemic insulin action, glucose and insulin tolerance tests were 
performed. [Klf3.sup.-/-] mice had better glucose tolerance than wild-type littermates (Fig. 3A). 
After high-fat feeding, glucose tolerance in wild-type mice was markedly reduced, as expected; 
however, [Klf3.sup.-/-] mice maintained an improved glucose tolerance, and the calculated area 
under the curve was not different from chow-fed [Klf3.sup.-/-] mice (Fig. 3B). We observed 
comparable insulin tolerance between genotypes on a chow or high-fat diet (Fig. 3C). While 
previous reports have indicated that elevated adipolin improves insulin sensitivity (23,24), it is 
possible that the inability to detect a change in [Klf3.sup.-/-] mice may be due to phenotypic 
effects resulting from the deregulation of KLF3 target genes other than Fam132a. High-fat feeding 
increased the fasting insulin-to-glucose ratio, a marker of insulin resistance (31) in wild-type mice 
but not [Klf3.sup.-/-] mice (Fig. 3D). KLF3-deficient mice tended to have a reduced insulin-to-
glucose ratio, but this was not significantly different from wild-type controls on either diet. 
[Klf3.sup.-/-] mice blood biochemistry. To further investigate the metabolic phenotype of 
[Klf3.sup.-/-] mice, we examined the plasma levels of a number of key metabolic indicators (Table 
1). We noted that despite improved glucose tolerance, [Klf3.sup.-/-] mice have a slight, but 
nonsignificant, elevation in fasting blood glucose (Table 1, chow-fed [Klf3.sup.+/+] vs. [Klf3.sup.-/-
]). High-fat feeding increased plasma insulin and leptin levels in wild-type and [Klf3.sup.-/-] mice; 
however, the increase in leptin levels in the fat-fed [Klf3.sup.-/-] mice was significantly lower than 
in wild-type. On a chow diet, KLF3 deficiency increased plasma adiponectin levels, while high-fat 
feeding did not significantly reduce levels in either genotype. Plasma triglyceride and  
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NEFA fatty acid levels were unchanged between genotypes and diets. 
 Fam132a, the gene coding for adipolin, is upregulated in KLF3-deficient tissue. Having 
found no measurable differences in acute energy balance between wild-type and lean [Klf3.sup.-/-
] mice, we explored alternative mechanisms to determine an explanation for this beneficial 
phenotype. We revisited previous microarray analysis, in which we had examined gene 
expression in erythrocytes that lack KLF3 (32), and also carried out further arrays to compare 
gene expression in several wild-type and [Klf3.sup.-/-] metabolic tissues (white adipose, red 
skeletal muscle, and liver). When comparing gene expression between wild-type and [Klf3.sup.-/-] 
tissues, we found that in a number of samples Fam132a was one of the most highly upregulated 
genes in [Klf3.sup.-/-] cells. This was an intriguing finding, as Fam132a is the gene that codes for 
the recently identified insulin-sensitizing factor adipolin, shown to promote glucose tolerance and 
insulin sensitivity in animal models of obesity and diabetes (23,24). In order to validate this 
FIG. 1. Klf32/2 mice are lean and resistant to diet-induced obesity. A: Body length of 9-week-old male mice on chow diet (Klf3+/+, n = 8; Klf32/2, n =
5). Data are means 6 SEM. ***P< 0.001. B and C: Male body weight with respect to age. Mice were placed on chow diet (Klf3+/+, n = 48; Klf3+/2, n =
57; and Klf32/2, n = 11) (B) or high-fat diet (C) from age 3–12 weeks (Klf3+/+, n = 20; Klf3+/2, n = 24; and Klf32/2, n = 6). D–G: Tissue weights as
determined by dissection and individual weighing of tissues in chow diet (Klf3+/+, n = 31; Klf3+/2, n = 53; and Klf32/2, n = 11) (D and F) and high-fat
diet (Klf3+/+, n = 25; Klf3+/2, n = 20; and Klf32/2, n = 6) (E and G). BAT, brown adipose tissue; EPI, epididymal; ING, inguinal subcutaneous; RP,
retroperitoneal. Data are means 6 SEM. *P < 0.05, **P < 0.01, ***P < 0.001, Klf3+/+ vs. Klf32/2; #P < 0.05, ##P < 0.01, ###P < 0.001, Klf3+/2 vs.
Klf32/2. H: Representative photographs of hematoxylin-eosin stained epididymal WAT (320 magniﬁcation) from Klf3+/+ and Klf32/2 male mice fed
either chow or high-fat diet. I: Size distribution of epididymal adipocytes. Left panel: Adipocytes from male mice on chow diet. Right panel:
Adipocytes from male mice on high-fat diet. Klf3+/+, n = 2–7; Klf32/2, n = 3–6 (200–300 cells measured per mouse).
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observation, we examined Fam132a gene expression using real-time RT-PCR in several tissues 
isolated from wild-type and [Klf3.sup.-/-] mice. We found that expression of the Fam132a gene is 
significantly upregulated in heart, lung, gut, bone marrow, and spleen in the absence of its 
repressor KLF3 (Fig. 4A). In particular, our examination of bone marrow and spleen revealed that 
Fam132a mRNA is readily detectable in wild-type erythroid tissue and that this high-level 
expression is significantly increased in cells lacking KLF3. This derepression is also observed in 
epididymal WAT of KLF3-deficient mice but not in brown adipose tissue (Fig. 4B and C). In 
agreement with this, [Klf3.sup.-/-] mice also show significantly elevated plasma adipolin levels on 
both chow and high-fat diets (Fig. 4D). 
 KLF3 binds and represses the Fam132a promoter in vitro and in vivo. Having determined 
that Fam132a gene expression is significantly upregulated in KLF3-null tissue (32), we 
investigated whether KLF3 can directly bind the Fam132a promoter by EMSA. An inspection of 
the Fam132a proximal promoter revealed the presence of several consensus KLF3-binding sites 
(25) (Fig. 5A). Three probes were designed to provide full coverage of these sites, and the binding 
of KLF3 to each of these probes was assessed by EMSA (Fig. 5B). KLF3 bound robustly to all 
three probes in comparison with a control sequence derived from the Klf8 proximal promoter, 
which has previously been validated as a KLF3 target both in vitro by EMSA and in vivo by ChIP 
assays (29). The addition of an anti-KLF3 antibody resulted in supershift of the most prominent 
probe complexes, confirming the presence of KLF3 (Fig. 5B). In addition to the major bands, 
slower migrating complexes were also observed, in particular for probes B and C, which could be 
supershifted by the addition of anti-KLF3 antibody. The presence of these higher-order complexes 
raises the possibility that precise regulation of the Fam132a promoter may depend upon multiple 
KLF3 occupancy and is concordant with the presence of multiple CACCC-box binding sites. 
 To demonstrate that KLF3 regulates Fam132a promoter activity, we performed transient 
transactivation assays using a luciferase reporter gene under the control of the Fam132a proximal 
promoter. We first tested the ability of KLF3 to repress promoter activity in Drosophila SL2 cells 
(Fig. 5C), which are conventionally used for such assays, as they lack the ubiquitously expressed 
CACCC-box binding proteins found in mammalian cells (26). In these reporter assays, we used 
KLF1, a transcriptional activator closely related to KLF3 (33), to drive the Fam132a promoter and 
found that including increasing doses of KLF3 in the assay resulted in strong downregulation of 
the active promoter. These effects were not observed for a control reporter that lacked the 
Fam132a promoter or a mutant version of the promoter from which the major KLF3 binding sites 
had been deleted, thereby confirming that KLF3 can repress Fam132a gene expression. To 
address whether KLF3 can repress the Fam132a promoter in a physiologically relevant 
mammalian cell line, we next repeated our reporter assays in 3T3-L1 cells (Fig. 5D). We found 
that the Fam132a promoter is robustly activated by endogenous factors when transfected into 
3T3-Lls and addition of KLF3 again resulted in dose-dependent repression of this activity. 
Mutation of the CACCC boxes in the promoter resulted in weaker activation by endogenous 
factors and noticeably reduced KLF3-mediated repression. 
 Finally, we used ChIP to show that endogenous KLF3 binds to the Fam132a promoter in 
vivo (Fig. 5E). We first examined 3T3-L1 cells and found significant enrichment of KLF3 at the 
Fam132a proximal promoter. In agreement with a previous study (14), we also detected binding of 
KLF3 at the C/ebp[alpha] promoter but observed only background levels of KLF3 at known 
negative control regions in the C/ebp[alpha] and Klf8 gene loci (14,29). As our previous 
microarray studies had shown that Fam132a expression is most notably derepressed in erythroid 
tissue (32), we decided to investigate binding of KLF3 to the Fam132a promoter in murine 
erythroleukemia cells, an erythroid cell line particularly amenable to ChIP analysis (Fig. 5F). Our 
analysis revealed significant enrichment of KLF3 at the Fam132a gene, using primers covering a 
region of the proximal promoter rich in KLF3 consensus binding sites (Fig. 5A). This enrichment 
was greater than that seen at a site in the Klf8 proximal promoter, which has previously been 
confirmed to be bound by KLF3 both in vitro and in vivo (29). Only background binding of KLF3 
was observed at negative control regions in the Klf8 promoter, and no significant precipitation of 
chromatin was seen for immunoglobulin controls. 
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as kJ/day (Fig. 2A) or when corrected for body weight
(data not shown). Similarly, loss of KLF3 did not appear to
alter fecal weight or energy content on either diet (Fig.
2B). Furthermore, total energy expenditure was not af-
fected by Klf3 deﬁciency when expressed per mouse or
per gram of lean body mass, as determined by dual-energy
X-ray absorptiometry (Fig. 2C–E). High-fat feeding signiﬁ-
cantly increased energy expenditure in wild-type and
Klf32/2 mice (Fig. 2F).
Klf32/2 mice are protected from diet-induced glucose
intolerance. For assessment of the effect of KLF3 de-
ﬁciency on systemic insulin action, glucose and insulin
tolerance tests were performed. Klf32/2 mice had better
glucose tolerance than wild-type littermates (Fig. 3A). Af-
ter high-fat feeding, glucose tolerance in wild-type mice
was markedly reduced, as expected; however, Klf32/2
mice maintained an improved glucose tolerance, and the
calculated area under the curve was not different from
chow-fed Klf32/2mice (Fig. 3B). We observed comparable
insulin tolerance between genotypes on a chow or high-fat
diet (Fig. 3C). While previous reports have indicated that
elevated adipolin improves insulin sensitivity (23,24), it is
possible that the inability to detect a change in Klf32/2
mice may be due to phenotypic effects resulting from the
deregulation of KLF3 target genes other than Fam132a.
High-fat feeding increased the fasting insulin-to-glucose
FIG. 2. No differences were detected in energy intake or output between Klf3+/+ and Klf32/2mice. A: Food intake was measured daily over 3 days in
male 12-week Klf3+/+ (n = 7–9) and Klf32/2 (n = 5–6) mice fed either chow or high-fat diet. B: Energy in feces was determined by bomb calorimetry
and data corrected for daily fecal output. Klf3+/+, n = 10; Klf32/2, n = 7–8. C and D: Total energy expenditure determined from VO2 and expressed as
kJ/day per mouse and per gram of lean body mass (n = 7–10 per group). Data are means 6 SEM. **P < 0.01, ***P < 0.001, chow vs. high-fat diet by
ANCOVA. E and F: Relationship between individual energy expenditure data calculated as heat production and lean body mass; diet, but not
genotype, signiﬁcantly affects energy expenditure.
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ratio, a marker of insulin resistance (31) in wild-type mice
but not Klf32/2 mice (Fig. 3D). KLF3-deﬁcient mice tended
to have a reduced insulin-to-glucose ratio, but this was not
signiﬁcantly different from wild-type controls on either diet.
Klf32/2 mice blood biochemistry. To further investigate
the metabolic phenotype of Klf32/2 mice, we examined
the plasma levels of a number of key metabolic indicators
(Table 1). We noted that despite improved glucose toler-
ance, Klf32/2 mice have a slight, but nonsigniﬁcant, ele-
vation in fasting blood glucose (Table 1, chow-fed Klf3+/+
vs. Klf32/2). High-fat feeding increased plasma insulin and
leptin levels in wild-type and Klf32/2 mice; however, the
increase in leptin levels in the fat-fed Klf32/2 mice was
signiﬁcantly lower than in wild-type. On a chow diet, KLF3
deﬁciency increased plasma adiponectin levels, while high-
fat feeding did not signiﬁcantly reduce levels in either
genotype. Plasma triglyceride and NEFA fatty acid levels
were unchanged between genotypes and diets.
Fam132a, the gene coding for adipolin, is upregulated
in KLF3-deﬁcient tissue. Having found no measurable
differences in acute energy balance between wild-type and
lean Klf32/2 mice, we explored alternative mechanisms to
determine an explanation for this beneﬁcial phenotype. We
revisited previous microarray analysis, in which we had
examined gene expression in erythrocytes that lack KLF3
(32), and also carried out further arrays to compare gene
expression in several wild-type and Klf32/2 metabolic tis-
sues (white adipose, red skeletal muscle, and liver). When
comparing gene expression between wild-type and Klf32/2
tissues, we found that in a number of samples Fam132a
was one of the most highly upregulated genes in Klf32/2
cells. This was an intriguing ﬁnding, as Fam132a is the gene
TABLE 1
Summary of plasma metabolic parameters for Klf3+/+ and Klf32/2 mice
Genotype Diet
Blood glucose
(mmol/L)
Insulin
(pmol/L)
Leptin
(pg/mL)
Adiponectin
(ng/mL)
Triglyceride
(mg/mL)
NEFA fatty
acids (mmol/L)
Klf3+/+ Chow 5.8 6 0.2 64 6 9 549 6 108 3,651 6 340 0.26 6 0.06 1.6 6 0.3
Klf32/2 Chow 7.0 6 0.4 44 6 11 341 6 97 5,515 6 587# 0.17 6 0.05 1.4 6 0.2
Klf3+/+ Fat 5.9 6 0.5 142 6 21** 4,486 6 938*** 3,429 6 387 0.17 6 0.05 1.7 6 0.1
Klf32/2 Fat 6.3 6 0.5 117 6 21* 1,316 6 627### 4,134 6 351 0.12 6 0.03 1.4 6 0.3
Data are means6 SE. Shown are plasma levels for key metabolic indicators comparing wild-type and Klf32/2male mice on chow and high-fat
diets. Between 6 and 20 mice were analyzed for each genotype. P values indicate the statistical difference between two means. #P , 0.05,
effect of genotype (two-tailed t test). **P , 0.01, ***P , 0.001, *P , 0.05, effect of diet. ###P , 0.001, effect of genotype (two-tailed t test).
FIG. 3. Klf32/2 mice are protected from diet-induced glucose intolerance and insulin resistance. A: Glucose tolerance test (2 g glucose/kg) in mice fasted
for 15 h. Data are means6 SEM. *P< 0.05, **P< 0.01, ***P< 0.001, Klf3+/+ vs. Klf32/2 ; #P< 0.05, ##P< 0.01, chow vs. high-fat diet (n = 7–19). B: Area
under the curve for glucose tolerance test. *Effect of genotype. #Effect of diet. *P < 0.05, ***P < 0.001, Klf3+/+ vs. Klf32/2 ; ##P < 0.001 chow vs. high-fat
diet (n = 7–19).C: Change in blood glucose levels during an insulin tolerance test (0.5 units insulin/kg) inmice fasted for 4 h (n = 8–17).D: Insulin resistance
index calculated from fasting plasma insulin and blood glucose levels. Data are means 6 SEM. *P < 0.05, chow-fed Klf3+/+ vs. high-fat diet–fed Klf3+/+.
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ratio, a marker of insulin resistance (31) in wild-type mice
but not Klf32/2 mice (Fig. 3D). KLF3-deﬁcient mice tended
to have a reduced insulin-to-glucose ratio, but this was not
signiﬁcantly different from wild-type controls on either diet.
Klf32/2 mice blood biochemistry. To further investigate
the metabolic phenotype of Klf32/2 mice, we examined
the plasma lev ls of a number of key metabolic indicators
(Table 1). We noted that despite improved glucose toler-
ance, Klf32/2 mic have a slight, but nonsigniﬁcant, ele-
vation in fasting blood glucose (Table 1, chow-fed Klf3+/+
vs. Klf32/2). High-fat feeding increased plasma insulin and
leptin levels in wild-type and Klf32/2 mice; however, the
increase in leptin levels in the fat-fed Klf32/2 mice was
signiﬁcantly lower than in wild-type. On a chow diet, KLF3
deﬁciency increased plasma adiponectin levels, while high-
fat feeding did not signiﬁcantly reduce levels in either
genotype. Plasma triglyceride and NEFA fatty acid levels
were unchanged between genotypes and diets.
Fam132a, the gene coding for adipolin, is upregulated
in KLF3-deﬁcient tissue. Having found no measurable
differences in acute energy balance between wild-type and
lean Klf32/2 mice, we explored alternative mechanisms to
determine an explanation for this beneﬁcial phenotype. We
revisited previous microarray analysis, in which we had
examined ge e expression in erythrocytes that ack KLF3
(32), and also carried out further arrays to compare gene
expression in several wild-type and Klf32/2 metabolic tis-
sues (white adipose, red skeletal muscle, and liver). When
comparing gene expression between wild-type and Klf32/2
tissues, we found that in a number of samples Fam132a
was one of the most highly upregulated genes in Klf32/2
cells. This was an intriguing ﬁnding, as Fam132a is the gene
TABLE 1
Summary of plasma metabolic parameters for Klf3+/+ and Klf32/2 mice
Genotype Diet
Blood glucose
(mmol/L)
Insulin
(pmol/L)
Leptin
(pg/mL)
Adiponectin
(ng/mL)
Triglyceride
(mg/mL)
NEFA fatty
acids (mmol/L)
Klf3+/+ Chow 5.8 6 0.2 64 6 9 549 6 108 3,651 6 340 0.26 6 0.06 1.6 6 0.3
Klf32/2 Chow 7.0 6 0.4 44 6 11 41 6 97 5,515 6 587# 0.17 6 0.05 1.4 6 0.2
Klf3+/+ Fat 5.9 6 0.5 142 6 21** 4,486 6 938*** 3,429 6 387 0.17 6 0.05 1.7 6 0.1
Klf32/2 Fat 6.3 6 0.5 117 6 21* 1,316 6 627### 4,134 6 351 0.12 6 0.03 1.4 6 0.3
Data are means6 SE. Shown are plasma levels for key metabolic indicators comparing wild-type and Klf32/2male mice on chow and high-fat
diets. Between 6 and 20 mice were analyzed for each genotype. P values indicate the statistical difference between two means. #P , 0.05,
effect of genotype (two-tailed t test). **P , 0.01, ***P , 0.001, *P , 0.05, effect of diet. ###P , 0.001, effect of genotype (two-tailed t test).
FIG. 3. Klf32/2 mice are protected from diet-induced glucose intolerance and insulin resistance. A: Glucose tolerance test (2 g glucose/kg) in mice fasted
for 15 h. Data are means6 SEM. *P< 0.05, **P< 0.01, ***P< 0.001, Klf3+/+ vs. Klf32/2 ; #P< 0.05, ##P< 0.01, chow vs. high-fat diet (n = 7–19). B: Area
under the curve for glucose tolerance test. *Effect of genotype. #Effect of diet. *P < 0.05, ***P < 0.001, Klf3+/+ vs. Klf32/2 ; ##P < 0.001 chow vs. high-fat
diet (n = 7–19).C: Change in blood glucose levels during an insulin tolerance test (0.5 units insulin/kg) inmice fasted for 4 h (n = 8–17).D: Insulin resistance
index calculated from fasting plasma insulin and blood glucose levels. Data are means 6 SEM. *P < 0.05, chow-fed Klf3+/+ vs. high-fat diet–fed Klf3+/+.
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FIG. 4. Fam132a gene expression and adipolin protein levels are increased in selected tissues in Klf32/2 mice. A: Fam132a mRNA expression in
various tissues, as determined by real-time quantitative PCR (n = 3 for each genotype). B: Fam132a mRNA expression in epididymal WAT (n = 6
for each genotype). C: Fam132a mRNA expression in brown adipose tissue (n = 6 for each genotype). For panels A, B, and C, the relative ex-
pression of Fam132a mRNA was normalized against 18S rRNA, and the expression level of the lowest sample was set to 1.0. Error bars represent
SEM. P values indicate the statistical difference between means (Klf3+/+ vs. Klf32/2): *P < 0.05, **P < 0.01 (two-tailed t test). D: Adipolin protein
levels in plasma of Klf3+/+ and Klf32/2 mice. Equal aliquots of diluted total plasma (1:20 in PBS) were resolved by SDS-PAGE and Western blotted
with an anti-adipolin antibody to determine the relative concentration of plasma adipolin. The positions of molecular weight standards in kDa are
indicated on the right-hand side of the blot. ***P < 0.001, Klf3+/+ vs. Klf32/2 (n = 11–29). BAT, brown adipose tissue.
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FIG. 5. KLF3 binds the Fam132a promoter in vitro and in vivo and is able to repress its activity. A: Probe design to assess binding of KLF3 to the
Fam132a proximal promoter by EMSA: three probes (probes A, B, and C) were designed to provide coverage of major CACCC boxes identiﬁed in
the promoter. Black arrows indicate CACCC boxes; numbering is with respect to the transcriptional start site. B: EMSA; KLF3 was expressed in
COS-7 cells and binding of nuclear extracts to probe A (lanes 4 and 5), probe B (lanes 6 and 7), and probe C (lanes 8 and 9) assessed. Also shown
is binding of KLF3 to a previously validated consensus sequence in the Klf8 promoter (29) (lanes 2 and 3). Binding of untransfected COS nuclear
extract to the Klf8 probe is shown in lane 1. a-KLF3 indicates an anti-KLF3 antibody used in supershift to validate KLF3 speciﬁc binding. Arrows
show the positions of probe complexes bound by KLF3. *KLF3, higher-order multimeric complexes. **KLF3, supershift complexes. C: SL-2 cells
were transiently transfected with either pGL4.10[luc2], pGL4.10[luc2] containing a region of the wild-type Fam132a proximal promoter, or
pGL4.10[luc2] containing a mutant version of the promoter lacking major CACCC boxes (Fam132aDCACCC). pPac-KLF1 (250 ng) was used to
drive activation of the reporter constructs. Increasing amounts of pPac-KLF3 were included to assess repression: 0 ng (lanes 1, 5, and 9), 25 ng
(lanes 2, 6, and 10), 50 ng (lanes 3, 7, and 11), and 250 ng (lanes 4, 8, and 12). Renilla vector pGL4.74[HRluc/TK] (1 mg) was used as a transfection
control. Shown is the average of three replicates, with error bars representing SEM. Also included is a cartoon summarizing the luciferase reporter
assay strategy. White arrows represent Fam132a promoter CACCC boxes, which can be bound by either KLF1 to drive luciferase activity or by
KLF3 to repress expression. Luc, luciferase reporter gene. D: 3T3-L1 cells were transiently transfected with either pGL4.10[luc2], pGL4.10[luc2]
containing a region of the wild-type Fam132a proximal promoter, or pGL4.10[luc2] containing a mutant version of the promoter lacking major
CACCC boxes (Fam132aDCACCC). Cells were transfected with increasing amounts of pCDNA3-KLF3 to assess repression: 0 ng (lanes 1, 5, and
9), 50 ng (lanes 2, 6, and 10), 250 ng (lanes 3, 7, and 11), and 500 ng (lanes 4, 8, and 12). Renilla vector pGL4.74[HRluc/TK] (1 mg) was used as
a transfection control. Shown is the average of three replicates, with error bars representing SEM. E and F: In vivo binding of KLF3 to the en-
dogenous Fam132a promoter was assessed in 3T3-LI (E) and murine erythroleukemia (F) cells by ChIP. Assays were carried out in duplicate for
KLF3 REGULATES ADIPOLIN
2734 DIABETES, VOL. 62, AUGUST 2013 diabetes.diabetesjournals.org
that codes for the recently identiﬁed insulin-sensitizing
factor adipolin, shown to promote glucose tolerance and
insulin sensitivity in animal models of obesity and diabetes
(23,24). In order to validate this observation, we examined
Fam132a gene expression using real-time RT-PCR in sev-
eral tissues isolated from wild-type and Klf32/2 mice. We
found that expression of the Fam132a gene is signiﬁcantly
upregulated in heart, lung, gut, bone marrow, and spleen in
the absence of its repressor KLF3 (Fig. 4A). In particular,
our examination of bone marrow and spleen revealed that
Fam132amRNA is readily detectable in wild-type erythroid
tissue and that this high-level expression is signiﬁcantly
increased in cells lacking KLF3. This derepression is also
observed in epididymal WAT of KLF3-deﬁcient mice but not
in brown adipose tissue (Fig. 4B and C). In agreement with
this, Klf32/2 mice also show signiﬁcantly elevated plasma
adipolin levels on both chow and high-fat diets (Fig. 4D).
KLF3 binds and represses the Fam132a promoter in
vitro and in vivo. Having determined that Fam132a gene
expression is signiﬁcantly upregulated in KLF3-null tissue
(32), we investigated whether KLF3 can directly bind
the Fam132a promoter by EMSA. An inspection of the
Fam132a proximal promoter revealed the presence of
several consensus KLF3-binding sites (25) (Fig. 5A). Three
probes were designed to provide full coverage of these
sites, and the binding of KLF3 to each of these probes was
assessed by EMSA (Fig. 5B). KLF3 bound robustly to all
three probes in comparison with a control sequence de-
rived from the Klf8 proximal promoter, which has pre-
viously been validated as a KLF3 target both in vitro by
EMSA and in vivo by ChIP assays (29). The addition of an
anti-KLF3 antibody resulted in supershift of the most
prominent probe complexes, conﬁrming the presence of
KLF3 (Fig. 5B). In addition to the major bands, slower
migrating complexes were also observed, in particular
for probes B and C, which could be supershifted by the
addition of anti-KLF3 antibody. The presence of these
higher-order complexes raises the possibility that precise
regulation of the Fam132a promoter may depend upon
multiple KLF3 occupancy and is concordant with the
presence of multiple CACCC-box binding sites.
To demonstrate that KLF3 regulates Fam132a promoter
activity, we performed transient transactivation assays
using a luciferase reporter gene under the control of the
Fam132a proximal promoter. We ﬁrst tested the ability of
KLF3 to repress promoter activity in Drosophila SL2 cells
(Fig. 5C), which are conventionally used for such assays,
as they lack the ubiquitously expressed CACCC-box
binding proteins found i mammalian cells (26). I these
reporter assays, we used KLF1, a transcription l activator
closely related to KLF3 (33), to drive the Fam132a pro-
moter and found that including increasing doses of KLF3
in the assay resulted in strong downregulation of the active
promoter. These effects were not observed for a control
reporter that lacked the Fam132a promoter or a mutant
versi n of the promoter from which the major KLF3
binding sites had been deleted, thereby conﬁrming that
KLF3 can repress Fam132a gene expression. To address
whether KLF3 can repress th Fam132a promoter in
a physiologically relevant mammalian cell line, we next
repeated our reporter assays in 3T3-L1 cells (Fig. 5D). We
found that the Fam132a promoter is robustly activated by
endogenous factors when transfected into 3T3-L1s and
addition of KLF3 again resulted in dose-dependent re-
pression of this activity. Mutation of the CACCC boxes in
the promoter resulted in weaker activation by endogenous
factors and noticeably reduced KLF3-mediated repression.
Finally, we used ChIP to show that endogenous KLF3
binds to the Fam132a promoter in vivo (Fig. 5E). We ﬁrst
examined 3T3-L1 cells and found signiﬁcant enrichment of
KLF3 at the Fam132a proximal promoter. In agreement
with a previous study (14), we also detected binding of
KLF3 at the C/ebpa promoter but observed only back-
ground levels of KLF3 at known negative control regions in
the C/ebpa and Klf8 gene loci (14,29). As our previous
microarray studies had shown that Fam132a expression is
most notably derepressed in erythroid tissue (32), we de-
cided to investigate binding of KLF3 to the Fam132a
promoter in murine erythroleukemia cells, an erythroid
cell line particularly amenable to ChIP analysis (Fig. 5F).
Our analysis revealed signiﬁcant enrichment of KLF3 at
the Fam132a gene, using primers covering a region of the
proximal promoter rich in KLF3 consensus binding sites
(Fig. 5A). This enrichment was greater than that seen at
a site in the Klf8 proximal promoter, which has previously
been conﬁrmed to be bound by KLF3 both in vitro and in
vivo (29). Only background binding of KLF3 was observed
at negative control regions in the Klf8 promoter, and no
signiﬁcant precipitation of chromatin was seen for immu-
noglobulin controls.
DISCUSSION
Given the current worldwide epidemic of diet-induced
obesity, there is considerable interest in understanding the
factors and molecular mechanisms that control physio-
logical responses to metabolic stimuli and how dysregu-
lation of these mechanisms can lead to the metabolic
disturbances of glucose intolerance, insulin resistance, and
type 2 diabetes. We have previously reported that mice
deﬁcient in the transcriptional regulator KLF3 are lean
with disrupted adipogenesis (14). In this study, we show
that this phenotype is the result of reduced adipocyte size
and number and that deletion of the Klf3 gene in vivo
results in reduction of WAT depots (subcutaneous and
visceral) and liver weight. We also examined the effect of
high-fat diet on body mass and found that the absence of
KLF3 offers partial protection from obesity, despite no
observable change i food intake, energy expenditure, or
energy excretion. In addition, glucose tolerance is im-
proved in Klf32/2 mice compared with Klf3+/+ littermates,
and high-fat feeding has no signiﬁcant effect on glucose
learance in knockout mice.
To further explore mechanisms underlying the lean
phenotype of Klf32/2 mice, we examined previous micro-
array data to identify genes whose deregulation might ex-
plain the observed resistance to diet-induced obesity,
improved glucose tolerance, and insulin sensitivity seen in
the absence of KLF3 (32). Thi analysis revealed that the
3T3-L1 cells and in triplicate for murine erythroleukemia cells. Enrichment was determined by real-time PCR and is relative to input signal and IgG
precipitated controls. The lowest signals for anti-KLF3 precipitated chromatin were each set to 1.0. Also shown is KLF3 enrichment at previou ly
reported positive control regions in the Klf8 and C/ebpa promoters and additional negative control regions in the Klf8 and C/ebpa locus, where
KLF3 has been shown not to bind (14,29). Error bars show SEM; P values indicate the statistical difference between means for Fam132a, C/ebpa,
or Klf8 promoters and negative control region 1 in the Klf8 gene locus. **P < 0.01, *P < 0.05.
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DISCUSSION 
 
Given the current worldwide epidemic of diet-induced obesity, there is considerable interest in 
understanding the factors and molecular mechanisms that control physiological responses to 
metabolic stimuli and how dysregulation of these mechanisms can lead to the metabolic 
disturbances of glucose intolerance, insulin resistance, and type 2 diabetes. We have previously 
reported that mice deficient in the transcriptional regulator KLF3 are lean with disrupted 
adipogenesis (14). In this study, we show that this phenotype is the result of reduced adipocyte size 
and number and that deletion of the Klf3 gene in vivo results in reduction of WAT depots 
(subcutaneous and visceral) and liver weight. We also examined the effect of high-fat diet on body 
mass and found that the absence of KLF3 offers partial protection from obesity, despite no 
observable change in food intake, energy expenditure, or energy excretion. In addition, glucose 
tolerance is improved in [Klf3.sup.-/-] mice compared with [Klf3.sup.+/+] littermates, and high-fat 
feeding has no significant effect on glucose clearance in knockout mice. 
 To further explore mechanisms underlying the lean phenotype of [Klf3.sup.-/-] mice, we examined 
previous micro-array data to identify genes whose deregulation might explain the observed 
resistance to diet-induced obesity, improved glucose tolerance, and insulin sensitivity seen in the 
absence of KLF3 (32). This analysis revealed that the gene coding for FAM132A/CTRP12/adipolin 
is upregulated in tissues lacking KLF3. Adipolin has recently been described as an adipokine 
capable of improving glucose tolerance and insulin sensitivity in both cell lines and mouse models 
of obesity and diabetes (23,24). Having identified this factor as a potential KLF3 target gene, we 
confirmed in vitro binding to the Fam132a proximal promoter by EMSA and also demonstrated by 
ChIP that endogenous KLF3 can interact with the promoter in vivo. We were also able to show that 
KLF3 can repress Fam132a promoter activity and demonstrate that expression of the Fam132a 
gene is significantly derepressed in several [Klf3.sup.-/-] tissues, including white adipose but not 
brown adipose tissue. Moreover, circulating plasma adipolin is markedly elevated in the absence of 
KLF3 on both chow and high-fat diets. 
 Upregulation of adipolin potentiates insulin release and improves glucose clearance in fed wild-
type mice. In the case of obese and leptin-deficient ob/ob mice, increased adipolin also drives 
improved glucose tolerance, which is associated with unchanged levels of insulin, suggesting 
improved insulin sensitivity (23,24). In addition, administration of adipolin in obese mice is reported 
to reduce body mass and adipocyte size. The effects of systemic upregulation of adipolin are 
therefore highly aligned to the metabolic phenotype of [Klf.sup.3-/]- mice. 
 Fam132a gene expression is increased in 3T3-L1 adipocytes treated with insulin or the insulin-
sensitizing drug rosiglitazone, while levels are reduced in adipose tissue from ob/ob mice, diet-
induced obese mice, and diabetic Zucker rats. Significantly, we found that elevated plasma adipolin 
levels are maintained in [Klf3.sup.-/-] obese mice. We also noted that serum fatty acids are 
unchanged in [Klf3.sup.-/-] mice, in agreement with previous observations that elevated adipolin 
does not affect their levels (23,24). Finally, in this work and previously (32), we observed high levels 
of Fam132a gene expression in erythroid tissue of [Klf3.sup.-/-] mice, suggesting that this is a 
potential additional source of the factor. 
The discovery that KLF3 regulates expression of a systemic factor capable of significantly 
improving whole body metabolism also offers a potential explanation for a longstanding paradox in 
which loss of KLF3 can drive adipogenesis at the cellular level but promote leanness in the whole 
animal (14). However, the capacity of adipolin to restrict body weight is currently unclear. To date, 
there have been two short-term studies on the effect of elevating systemic adipolin on body weight 
in obese mice, with one study reporting a modest but significant reduction in weight, while the other 
found no difference (23,24). It is possible that persistent upregulation of adipolin and, indeed, other 
factors in [Klf3.sup.-/-] mice may have a more profound effect on body weight. 
 We have observed that [Klf3.sup.-/-] male mice are lean and resistant to diet-induced obesity, yet 
show no detectable changes in energy metabolism. It is possible that this leanness is initiated 
during embryonic development or early postnatal life, with loss of KLF3 leading to changes in gene 
expression that cumulatively result in differences in adiposity that are apparent by weaning. It has 
previously been shown that programming of adipocyte cell number is set before adulthood with 
implications for fat mass and obesity later in life (34), and the involvement of KLF3 in 
developmental programs such as this may help explain the early-onset leanness of [Klf3.sup.-/-] 
mice. Given that this [Klf3.sup.-/-] mouse model is a global knockout, it is quite possible that the 
complex phenotype of these mice is influenced by the absence of KLF3 in a variety of tissues at 
different developmental time points. 
 In summary, we have identified the transcriptional repressor KLF3 as a regulator of Fam132a, the 
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gene coding for the insulin-sensitizing factor adipolin. We have demonstrated that mice deficient in 
KLF3 have significantly elevated plasma adipolin levels on both chow and high-fat diets and that 
this is associated with a lean phenotype and improved glucose tolerance and insulin sensitivity. 
Future studies aimed at modulating adipolin levels in [Klf3.sup.-/-] mice will reveal the extent to 
which the improved metabolic phenotype of these mice is dependent upon the systemic 
upregulation of plasma adipolin. In conclusion, regulating the activity of KLF3, potentially via 
targeting of upstream kinases, has the potential to inform future therapeutic strategies in the 
treatment of obesity and diabetes. 
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